Needham Maintains Buy on AtriCure, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has maintained a Buy rating on AtriCure (NASDAQ:ATRC) and raised the price target from $34 to $40.
October 30, 2024 | 10:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has maintained a Buy rating on AtriCure and increased the price target from $34 to $40, indicating a positive outlook.
The increase in the price target from $34 to $40 by Needham suggests a positive outlook for AtriCure, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100